Inadequate investigation of out-of-specification (OOS) results in the laboratory is a common observation cited in FDA 483s and Warning Letters. Regulatory investigators worldwide are closely scrutinizing laboratory operations, and FDA includes OOS investigations as a quality metric. Failure to investigate OOS results appropriately can constitute a data integrity issue—for example, retesting without justification, cherry-picking data, or “experimental” testing prior to GMP release testing. Establishing a clear, defined strategy before encountering an OOS is critical for compliance.
This live webinar will provide a detailed understanding of how a compliant laboratory manages testing and OOS investigations, and how laboratories interact with other functional units during the process. It will outline FDA guidance on handling OOS results and provide a clear process for compliant laboratory operations. Real-world examples from Chemistry and Microbiology in QC and manufacturing testing will also be discussed.
This Live Webinar Will Cover
Learning Benefits
Regulations and Guidances Covered
Who Should Attend
Peter H. Calcott, Ph.D. is President, Calcott Consulting which is focused on delivering solutions to pharmaceutical and biotechnology companies in the areas of corporate strategy, supply chain, quality, clinical development, regulatory affairs, corporate compliance and enterprise e-solutions. He is also an Academic Program Developer for the University of California, Berkeley’s Biotechnology and Pharmaceutics Postgraduate Programs. Prior to this he was VP at the executive team level at PDL BioPharma where he was responsible for development and implementation of Quality &...